Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 8905 results

  1. Cranial aneurysms

    All NICE products on cranial aneurysms. Includes any guidance and advice.

    Topic page

  2. Upper airways tract cancers

    All NICE products on upper airways tract cancers. Includes any guidance and quality standards.

    Topic page

  3. Embolism and thrombosis

    All NICE products on embolism and thrombosis. Includes any guidance, advice and quality standards.

    Topic page

  4. Heart failure

    All NICE products on heart failure. Includes any guidance, advice and quality standards.

    Topic page

  5. Aortic aneurysms

    All NICE products on aortic aneurysms. Includes any guidance and advice.

    Topic page

  6. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  7. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID6235]

    In development Reference number: GID-TA11246 Expected publication date:  05 March 2026

    Technology appraisal guidance
    In development

  8. Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)

    NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    16 February 2023

    Sections for TA867

  9. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)

    NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 April 2023

    Sections for TA879

  10. Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)

    NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    13 July 2023

    Sections for TA910

  11. Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) (TA899)

    NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 June 2023

    Sections for TA899

  12. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    20 June 2023

    Sections for TA901

  13. Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA889)

    NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    17 May 2023

    Sections for TA889

  14. Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) (TA884)

    NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    3 May 2023

    Sections for TA884

  15. Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)

    NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    23 November 2023

    Sections for TA932